Theravance Announces Initiation of Phase 2 Study with Its MARIN Compound, TD-9855, for the Treatment of ADHD
Theravance Announces Initiation of Phase 2 Study with Its MARIN Compound, TD-9855, for the Treatment of ADHD
Dec 12, 2011
Innoviva
Minimum 15 minutes delayed. Source: LSEG
Sign up to receive important email alerts & updates from Innoviva.
Sign up now